Aktuella utlysningar, vecka 35, 2022
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska utlysningar
Forskningsanslag - Parkinson Research Foundation
Stiftelsen delar årligen ut projektanslag om minst en miljon kronor antingen som ett enda eller uppdelat på ett fåtal anslag. Anslag söks en gång per år.
Ansökningsperioden för 2022 är öppen från den 1 september till och med den 30 september 2022. Ansökningsprocessen för 2022 är en öppen process. För ansökan om anslag, använd stiftelsens Ansökningsformulär. Ansökan ska skickas per email till firstname.lastname@example.org
Closing date: 30 September 2022
Forskningsanslag - Stiftelsen Läkare Mot AIDS Forskningsfond
Fonden ledigförklarar forskningsanslag för studier som syftar till behandling av HIV-infektion eller dess följdtillstånd och till förebyggande åtgärder. Upp till 400 000 kr kan anslås till varje beviljat projekt.
Projekt som har klinisk relevans prioriteras högt. Stor vikt läggs på att ansökningarnas utformning håller hög kvalitet. Resebidrag beviljas inte.
Closing date: 1 October 2022
Stipendium - Drottning Silvias Jubileumsfond
Stiftelsen Drottning Silvias Jubileumsfond ger bidrag till forskning om barn och funktionshinder.
Fonden delar årligen ut stipendier som kan sökas av studerande antagna till forskarbildning inom universitet och högskolor i landet. Varje år prioriteras ett visst forskningsområde som kungörs i samband med att inbjudan till ansökan annonseras. Årets tema: Studier av behandling/omhändertagande av barn med samsjuklighet/flerfunktionshinder.
Closing date: 1 October 2022
Stipendium - Ebba Danelius Stiftelse
Kan sökas av legitimerade sjuksköterskor som bedriver forskningsarbete eller utvecklingsarbeten kring hur ohälsa kan förebyggas och hur stöd kan ges till barn och unga. Ansökan får inte gälla studier rörande barnens föräldrar eller andra närstående vuxna. Stipendiets syfte är att minska ohälsa genom att bidra till ökad forskning om barn och ungas sjukdom, livsmiljö och hälsa.
Closing date: 7 October 2022
Forskningsanslag för forskning beträffande prostatacancer och bröstcancer - Percy Falks Stiftelse
Fonden instiftades 2001 genom testamente av direktör Percy Falk, Stockholm. Stiftelsen skall genom anslag främja vetenskaplig forskning och undervisning eller studieverksamhet i Sverige rörande prostatacancer och bröstcancer. Anslag kommer att utdelas under mars 2023. Tillgängligt belopp för utdelning är 2 000 000 kronor.
Closing date: 1 November 2022
EFSD new targets for diabetes or obesity-related metabolic diseases - European Association for the Study of Diabetes
The European Foundation for the Study of Diabetes, in partnership with Merck, Sharpe & Dome, invites applications for its call on new targets for diabetes or obesity-related metabolic diseases. This aims to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes or obesity-related metabolic diseases. Areas of research emphasis may include:
•new targets for improving skeletal; muscle or adipose tissue insulin resistance;
•the role of lipid droplets in the aetiology of metabolic fatty liver disease;
•mechanisms of glucose-dependent insulin and glucagon secretion;
•regulation of liver flat content by gut hormones or the microbiome.
Closing date: 1 December 2022
Increasing the understanding of the impact of underlying medical conditions and other risk factors of COVID-19 – Pfizer
Pfizer invites applications for its increasing the understanding of the impact of underlying medical conditions and other risk factors of COVID-19 funding opportunity. This supports research that increases the understanding of the impact of underlying medical conditions and other risk factors of COVID-19.
•increase understanding of a person’s risk profile and which comorbidities or characteristics increase a person’s risk of developing severe COVID-19;
•increase awareness on the importance of early testing after exposure to SARS-CoV-2 or in presence of suspected COVID-19 signs or symptoms;
•educate on the importance of treatment options available for patients with COVID-19 and at increased risk of developing severe disease;
•understand the needs of increased risk populations and defining the best channels to engage and communicate with them.
Closing date: 22 September 2022
Advances in migraine treatment - Pfizer
Pfizer invites applications for its advances in migraine treatment funding opportunity. This supports projects that focus on increasing the understanding of healthcare professionals on the management and care of people with migraine. Of particular interest are educational initiatives that encompass the following:
•unmet need and disease burden associated with migraine;
•the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine;
•anti-CGRP therapies for acute and prophylactic treatment of migraine.
Closing date: 11 October 2022
ASPIRE global obesity grant - Pfizer
Pfizer invites letters of intent for its ASPIRE global obesity grant. This supports basic science, preclinical research and clinical research, animal experimentation related to human biology and physiological, cellular, molecular and translational research regarding obesity.
Closing date: 11 October 2022
Daylight award - Velux Foundation
The Velux Foundation invites nominations for its daylight award. This recognises researchers and architects for their focus on daylight and its relation to humans, nature and technology.
PIs must be a permanent employee of a university or another permanent research institution. International and interdisciplinary collaborations are welcome.
Closing date: 30 September 2022
Federal Funding agencies
Notice of Intent to Publish a Funding Opportunity Announcement for Pediatric Heart Network Clinical Research Centers (UM1): NIH
The National Heart, Lung, and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications from qualified institutions willing to participate with NHLBI in the Pediatric Heart Network (PHN) as Clinical Research Centers (CRCs).
These Clinical Research Centers will be expected to support and conduct research to improve the health and quality of life for children and adults with congenital heart disease through multi-center collaborative clinical research. Collaboration among the Clinical Research Centers, the Data Coordinating Center and other stakeholders is expected to facilitate multi-center evaluation of medical, interventional and surgical therapies; provide a training platform for fellows, junior faculty, and nurses; support development of novel treatment techniques and methodologies; and promote dissemination of study results to improve the scientific basis for the care of affected individuals. NHLBI plans to issue a companion FOA for the PHN Data Coordinating Center.
The intended FOA is expected to be published in the Fall of 2022, with an expected application due date in Spring 2023.
Notice Number: NOT-HL-22-045
Physiomimetics and Organoids for Reproductive Health (R01, R21 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) invites grant applications to develop physiomimetic platforms and organoid culture systems for studies of the female reproductive tract and gametogenesis (both male and female) that can be used to uncover factors responsible for gynecological conditions and infertility.
This R01 FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA (RFA-HD-23-025).
Deadline: March 29, 2023 Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-HD-23-024 (R01); RFA-HD-23-025 (R21).
Fellow/Investigator/Consortium grants, Rally Foundation for Childhood Cancer Research (Rally) Foundation, US
Rally funds pediatric cancer research in the following areas:
- Innovative approaches to research which could lead to advanced studies or clinical trials.
- Basic science studies that are likely to lead to a new discovery.
- Personalized, targeted, alternative or integrative research proposals.
- Under-studied cancer types.
- Quality of life, survivorship and palliative care studies.
- Data utilization through data standardization, collection, storage, analysis and sharing.
- Fellow Grants – Grants are for one or two years of support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $50,000 per year.
- Young Investigator and Independent Investigator Grants – Grants are for one or two years of support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $50,000 per year.
- Consortium Grants (three or more institutions collaborating on a grant-supported research project): Grants are for one or two years of support. At the end of the award you may apply for additional funding the next grant cycle. Each funded grant will be awarded up to $100,000 per year.
Deadline: September 23, 2022 at 5:00 PM EST (LOI); January 6, 2023 at 5:00 PM EST (Full Proposal by invitation only).
IN-CYCLE GRANT, Alpha 1 Foundation, US
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of individuals affected by Alpha-1 worldwide.
The specific aims of the Grants Award Program are to promote research that would eventually result in the improved health of individuals with AAT Deficiency. The Program supports basic science and clinical research, improved understanding of the pathogenesis of the clinical manifestations of AAT Deficiency, the development and testing of treatments for the disease, bioethics and social research, and the promotion of education of members of the medical community regarding AAT Deficiency.
Bridge Grant: Up to $25,000, Up to 1 year.
Pilot and Feasibility Grant: Up to $75,000, Up to 1 year.
Postdoctoral Research Fellowship Grant: Up to $75,000/year, Up to 2 years.
Research Grant: Up to $100,000/year, Up to 2 years.
Deadline: September 30, 2022, 11:59PM ET (LOI); February 17, 2023, 11:59PM ET (Full proposal by invitation).
Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research, in Honor of John Robert Lewis, American Association for Cancer Research (AACR), US
The intent of this program is to support the development and diversity of talent working in pancreatic cancer research. Eligibility is limited to members of racial or ethnic groups that have been shown to be underrepresented in the cancer related sciences workforce.
This award represents a joint effort to encourage and support early career scientists engaged in pancreatic cancer research relevant to the goals and mission of the Lustgarten Foundation.
The grant provides $300,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient.
Deadline: October 18, 2022 1:00 PM (ET) (LOI); January 24, 2023 1:00 PM (ET) (Full proposal by invitation)
2022-2023 REQUEST FOR PROPOSALS, Melanoma Research Alliance (MRA), US
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment.
This cycle, proposals will be accepted for Established Investigator Awards, Academic-Industry Partnership Awards (for Established Investigators), Young Investigator Awards, Pilot Awards, and Special Opportunity Awards in Immunotherapy, Radiation Oncology, Metastatic Uveal Melanoma, and Patient-Centric Melanoma Clinical Trials. MRA plans to support at least $11.5 million in new funding in the 2022-2023 cycle.
Deadline: 11:59 p.m. Eastern Time, November 2, 2022.